Trials / Completed
CompletedNCT00401570
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
Phase 2 Open-Label Study of Volociximab (M200) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Not Previously Treated With Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volociximab | Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks. |
| DRUG | Gemcitabine | Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-11-20
- Last updated
- 2013-01-30
Locations
6 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00401570. Inclusion in this directory is not an endorsement.